Merck & Co. (MRK) Stock: Slips to $148.87 Despite Strong Melanoma Trial Results With Moderna

TLDR Merck stock dips 0.67% despite a 42% drop in melanoma recurrence or death risk. Merck and Moderna’s mRNA therapy cuts distant metastasis or death risk by 38%. Phase 3 melanoma trial reports 82.2% recurrence-free survival at two years. MRK falls to $148.87 even as personalized cancer therapy posts strong trial data. Merck and Moderna [...]

The post Merck & Co. (MRK) Stock: Slips to $148.87 Despite Strong Melanoma Trial Results With Moderna appeared first on Blockonomi.